Ginkgo Bioworks Holdings, Inc. (DNA) AI Stock Analysis

Founded in 2008 and based in Boston, Massachusetts, Ginkgo Bioworks Holdings, Inc. develops platforms for programming cells to produce a broad variety of products. Its bioengineering platform enables cells to manufacture therapeutics, food ingredients, and sustainable chemicals derived from petroleum. The company serves multiple sectors, including pharmaceuticals, specialty chemicals, agriculture, consumer goods, and food production. In addition to its core platform, Ginkgo Bioworks pursues strategic partnerships to widen its technological footprint, including a collaboration with Selecta Biosciences, Inc. to advance the ImmTOR technology platform for therapeutic development and immune modulation.

Ginkgo Bioworks achieved a 5-year revenue CAGR of 17.3% from FY2020 through FY2025, though annual revenue peaked at $477.7M in FY2022 before dropping to $251.5M in FY2023, $227.0M in FY2024, and $170.2M in FY2025. Gross margin expanded from 58.7% in FY2021 to 81.5% in FY2025. Operating margins remained negative throughout, recording -185.3% in FY2025 alongside a net income of -$312.8M. R&D spending declined from $1.15B in FY2021 to $243.8M in FY2025. In the trailing twelve months, revenue was $132.4M, with quarterly revenue falling 48.5% year-over-year for the period ended June 30, 2026.

As of June 30, 2026, Ginkgo Bioworks held $302.2M in cash and short-term investments against $404.1M in total debt, resulting in net debt of $102.0M. The company reported a current ratio of 4.57 and shareholders' equity of $420.3M, yielding a debt-to-equity ratio of 0.96. Operating cash flow in FY2025 was -$171.1M and free cash flow was -$178.7M. Capital expenditures totaled $7.7M in FY2025, while share issuance generated $19.5M as the share count expanded 62.2% over 5 years.

At a last close of $10.27, Ginkgo Bioworks had a market capitalization of $691.6M and an enterprise value of $679.7M. The stock trades at a price-to-sales ratio of 5.2x and an EV-to-revenue multiple of 5.1x, above the 4.1x price-to-sales median of its US-listed Healthcare peers. Its price-to-book multiple is 1.4x. Ginkgo Bioworks stock declined 32.1% over the past year compared to a 16.8% gain for the S&P 500 (SPY), and has fallen 97.8% over the past 5 years versus an 83.0% return for the index.

Analyst coverage consists of 0 Strong Buy, 0 Buy, 1 Hold, 1 Sell, and 1 Strong Sell rating. The mean price target is $8.00, which is 22.1% below the last closing price of $10.27. Ginkgo Bioworks beat EPS estimates in 1 of the last 4 quarters. For the fiscal year ending December 31, 2026, consensus expectations call for revenue of $85.1M and an EPS of -$2.93. For the following fiscal year, the single covering analyst projects revenue of $96.2M and an EPS of -$2.90. The company's next earnings date is November 5, 2026.

This page is an AI-written research summary of Ginkgo Bioworks Holdings, Inc. (DNA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DNA income statement, DNA balance sheet, DNA key metrics, DNA analyst forecast, DNA chart. See the DNA stock overview for the latest quote and news.